NORWALK, Connecticut – May 26, 2016 – A new clinical research trial was opened by the Western Connecticut Health Network (WCHN), Norwalk and Danbury Hospitals, called the RESOLVE Study. The study will explore a potential new treatment option for patients with metastatic pancreatic cancer (cancer that has spread to other parts of the body). “Metastatic pancreatic adenocarcinoma is one of the most difficult cancers to treat, so there’s an urgent need for more effective treatment approaches,” said Dr. Richard Frank, Director of Clinical Cancer Research for WCHN and principal investigator of the RESOLVE Study.
The objective of the RESOLVE Study is to evaluate the efficacy and safety of using the medications nab-paclitaxel and gemcitabine, in combination with ibrutinib, an oral medication presently FDA approved to treat various types of lymphoma and leukemia. Nab-paclitaxel and gemcitabine are presently approved by the FDA for the treatment of pancreatic cancer.
The RESOLVE Study seeks to enroll approximately 326 participants worldwide. All study participants will receive nab-paclitaxel and gemcitabine whereas the study medication ibrutinib will be given to some patients in a randomized fashion. Only individuals who have not received chemotherapy for advanced pancreatic cancer are eligible for the trial.
“Patients are essential and valued partners who play a critical role in the clinical research process,” said Dr. Frank. “Without their participation, new medications and the development of new therapies would not be possible.”
For more information about participating in the RESOLVE Study at either Danbury Hospital or Norwalk Hospital, please contact Jennifer Long at the Whittingham Cancer Center at Norwalk Hospital at (203) 852-2996.